Status:
COMPLETED
Selective Retina Therapy With Real-Time Feedback-Controlled Dosimetry for Treating Acute Idiopathic Central Serous Chorioretinopathy in Korean Patients
Lead Sponsor:
Kim's Eye Hospital
Conditions:
Central Serous Chorioretinopathy
Eligibility:
All Genders
20-55 years
Phase:
NA
Brief Summary
Selective retina therapy (SRT) selectively disrupts the retinal pigment epithelium (RPE) with minimal damage to the photoreceptors. Previous studies have shown SRT to be effective for resolving SRF, w...
Detailed Description
Central serous chorioretinopathy (CSC) is a disorder that is characterized by a localized serous detachment of the neurosensory retina in the posterior pole. Additionally, CSC is often self-limiting a...
Eligibility Criteria
Inclusion
- Patients diagnosed with treatment-naïve idiopathic central serous chorioretinopathy
Exclusion
- age \> 55 years,
- Clinical or angiographic features suggestive of choroidal neovascularization
- Optical coherence tomography findings suggestive of type 1 neovascularization or polypoidal choroidal vasculopathy (e.g., double layer sign or fibrovascular pigment epithelial detachment).
- History of macular laser photocoagulation, photodynamic therapy, or anti-vascular-endothelial growth factor therapy.
- History of exogenous corticosteroid treatment for a systemic disease (e.g., Cushing's syndrome or renal disease).
Key Trial Info
Start Date :
January 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2017
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT03339856
Start Date
January 1 2017
End Date
October 1 2017
Last Update
January 2 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.